VRDN-003

DRUG4 trials

Sponsors

Viridian Therapeutics, Inc.

Conditions

Thyroid Eye DiseaseThyroid Eye Disease (TED)

Phase 3

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

Active, not recruitingNCT06625411

Viridian Therapeutics, Inc.Thyroid Eye Disease

Start: 2024-08-27End: 2026-11-15Target: 117Updated: 2025-09-30

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

Active, not recruitingNCT06625398

Viridian Therapeutics, Inc.Thyroid Eye Disease

Start: 2024-08-27End: 2026-12-15Target: 195Updated: 2025-09-30

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

Active, not recruitingNCT06812325

Viridian Therapeutics, Inc.Thyroid Eye Disease (TED)

Start: 2025-02-03End: 2026-10-31Updated: 2025-12-18

A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

Active, not recruitingNCT07155668

Viridian Therapeutics, Inc.Thyroid Eye Disease

Start: 2025-07-01End: 2026-11-30Updated: 2026-01-14